A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Brain metastases
- Focus Therapeutic Use
- 04 Jun 2019 Results assessing efficacy of bevacizumab in patients with recurrent solid tumor brain metastases, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 29 Mar 2019 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.